Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 513160, 6 pages
http://dx.doi.org/10.1155/2014/513160
Review Article

Multiple Sclerosis and Pregnancy: Current Considerations

1Head of Neurology, “Carol Davila” University of Medicine and Pharmacy, Colentina Clinical Hospital, No. 19-21 Stefan cel Mare Avenue, 020125 Bucharest, Romania
2Department of Neurology, Colentina Clinical Hospital, No. 19-21 Stefan cel Mare Avenue, 020125 Bucharest, Romania

Received 29 November 2013; Accepted 24 December 2013; Published 7 April 2014

Academic Editors: V. M. Rivera and E. J. Thompson

Copyright © 2014 Ioan Buraga and Roxana-Elena Popovici. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Confavreux, M. Hutchinson, M. M. Hours, P. Cortinovis-Tourniaire, and T. Moreau, “Rate of pregnancy-related relapse in multiple sclerosis,” The New England Journal of Medicine, vol. 339, no. 5, pp. 285–291, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Giannini, E. Portaccio, A. Ghezzi et al., “Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study,” BMC Neurology, vol. 12, article 124, 2012. View at Google Scholar
  3. M. P. Amato, E. Portaccio, A. Ghezzi et al., “Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis,” Neurology, vol. 75, no. 20, pp. 1794–1802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Ferrero, S. Pretta, and N. Ragni, “Multiple sclerosis: management issues during pregnancy,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 115, pp. 3–9, 2004. View at Google Scholar
  5. S. Tomczyk, K. Wallace, S. Liu, and B. Sperling, “Pregnancy outcomes from the Avonex (interferon beta-1a) pregnancy exposure registry,” in Proceedings of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012.
  6. P. K. Coyle, S. Sinclair, A. E. Scheuerle, J. M. Thorpe, J. Albano, and M. Rametta, “Final results from the Betaseron (interferon beta-1b) Pregnancy Registry”.
  7. C. Weber-Schoendorfer and C. Schaefer, “Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study,” Multiple Sclerosis, vol. 15, no. 9, pp. 1037–1042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Patti, T. Cavallaro, S. Lo Fermo et al., “Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?” Journal of Neurology, vol. 255, no. 8, pp. 1250–1253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Boskovic, R. Wide, J. Wolpin, D. J. Bauer, and G. Koren, “The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort,” Neurology, vol. 65, no. 6, pp. 807–811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. G. G. Briggs, R. K. Freeman, and S. J. Yaffe, Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, Lippincott, Williams & Wilkins, Philadelphia, Pa, USA, 9th edition, 2011.
  11. A. E. Miller, S. Rustgi, and C. Farrell, “Use of glatiramer acetate during pregnancy: offering women a choice,” Multiple Sclerosis, vol. 18, supplement 4, 2012. View at Google Scholar
  12. Y. D. Fragoso, M. Boggild, M. A. Macias-Islas, A. Carra, K. D. Schaerer et al., “The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis,” Clinical Neurology and Neurosurgery, vol. 115, no. 2, pp. 154–159, 2013. View at Publisher · View at Google Scholar
  13. M. Sandberg-Wollheim, E. Alteri, M. S. Moraga, and G. Kornmann, “Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy,” Multiple Sclerosis, vol. 17, no. 4, pp. 423–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Hellwig and R. Gold, “Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis,” Journal of Neurology, vol. 258, no. 3, pp. 502–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Hellwig, A. Haghikia, M. Rockhoff, and R. Gold, “Multiple sclerosis and pregnancy: experience from a nationwide database in Germany,” Therapeutic Advances in Neurological Disorders, vol. 5, no. 5, pp. 247–253, 2012. View at Google Scholar
  16. N. G. Wehner, M. Skov, G. Shopp, M. S. Rocca, and J. Clarke, “Effects of natalizumab, an α4 integrin inhibitor, on fertility in male and female guinea pigs,” Birth Defects Research B—Developmental and Reproductive Toxicology, vol. 86, no. 2, pp. 108–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. “Biogen Idec Inc. Tysabri (natalizumab) prescribing information,” 2012, http://www.tysabri.com/pdfs/I61061-13_PI.pdf.
  18. K. Hellwig, A. Haghikia, and R. Gold, “Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment,” Multiple Sclerosis, vol. 17, no. 8, pp. 958–963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. GILENYA, “Summary of product characteristics,” http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf.
  20. GILENYA, “Prescribing Information,” http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf.
  21. W. Collins, G. Francis, G. Koren et al., “Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis,” in Proceedings of the 63rd annual meeting of the American Academy of Neurology, Honolulu, Hawaii, April 2011, P07. 184.
  22. R. Gold, J. T. Phillips, E. Havrdova et al., “BG-12 (dimethyl fumarate) and pregnancy: preclinical and clinical data from the clinical development program,” in Proceedings of the 65th Annual Meeting of the American Academy of Neurology, San Diego, Calif, USA, March 2013.
  23. Q. Wei, G. Runrong, S. Xiangdong et al., “Studies on teratogenicity of dimethyl fumarate,” Journal of Hygiene Research, vol. 19, pp. 28–31, 1990. View at Google Scholar
  24. TECFIDERA, “Summary of product characteristics,” http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf.
  25. “Immunex Corporation. Novantrone New Drug Application Pharmacology Review Part 2,” 2012, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21120.pdf_Novantrone_Pharmr_P2.pdf.
  26. “Genzyme Corporation, a Sanofi company. Aubagio (teriflunomide) prescribing information,” 2012, http://products.sanofi.us/aubagio/aubagio.pdf.
  27. A. Björk, S. Jönsson, T. Fex et al., Quinoline derivatives. Patent 6593343, USA, 2002.
  28. J. Thöne and R. Gold, “Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis,” Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 3, pp. 365–370, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. ZENAPAX, “Summary of product characteristics,” http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000198/WC500057604.pdf.
  30. A. Hviid and D. Mølgaard-Nielsen, “Corticosteroid use during pregnancy and risk of orofacial clefts,” Canadian Medical Association Journal, vol. 183, no. 7, pp. 796–804, 2011. View at Publisher · View at Google Scholar
  31. J. N. Hoes, J. W. G. Jacobs, M. Boers et al., “EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases,” Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1560–1567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Hellwig, C. Beste, S. Schimrigk, and A. Chan, “Immunomodulation and postpartum relapses in patients with multiple sclerosis,” Therapeutic Advances in Neurological Disorders, vol. 2, no. 1, pp. 7–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Achiron, I. Kishner, M. Dolev et al., “Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis,” Journal of Neurology, vol. 251, no. 9, pp. 1133–1137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Pakpoor, G. Disanto, V. L. Melanie, K. Hellwig, G. Giovannoni, and V. R. Sreeram, “Breastfeeding and multiple sclerosis relapses: a meta-analysis,” Journal of Neurology, vol. 259, no. 10, pp. 2246–2248, 2012. View at Google Scholar
  35. A. S. McNeilly, “Lactational control of reproduction,” Reproduction, Fertility and Development, vol. 13, no. 7-8, pp. 583–590, 2001. View at Google Scholar · View at Scopus
  36. C. Gregg, V. Shikar, P. Larsen et al., “White matter plasticity and enhanced remyelination in the maternal CNS,” Journal of Neuroscience, vol. 27, no. 8, pp. 1812–1823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. P. K. Coyle, S. Christie, P. Fodor et al., “Multiple sclerosis gender issues: clinical practices of women neurologists,” Multiple Sclerosis, vol. 10, no. 5, pp. 582–588, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Comi, M. Filippi, and J. S. Wolinsky, “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis,” Annals of Neurology, vol. 49, no. 3, pp. 290–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. D. Fragoso, A. Finkelsztejn, D. R. Kaimen-Maciel et al., “Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series,” CNS Drugs, vol. 24, no. 11, pp. 969–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Ford, P. Trigwell, and M. Johnson, “The nature of fatigue in multiple sclerosis,” Journal of Psychosomatic Research, vol. 45, no. 1, pp. 33–38, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Roullet, M.-H. Verdier-Taillefer, P. Amarenco, G. Gharbi, A. Alperovitch, and R. Marteau, “Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients,” Journal of Neurology Neurosurgery and Psychiatry, vol. 56, no. 10, pp. 1062–1065, 1993. View at Google Scholar · View at Scopus
  42. M. B. D'hooghe, P. Haentjens, G. Nagels, T. D'Hooghe, and J. De Keyser, “Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis,” Journal of Neurology, vol. 259, no. 5, pp. 855–861, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Runmarker and O. Andersen, “Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis,” Brain, vol. 118, no. 1, pp. 253–261, 1995. View at Google Scholar · View at Scopus
  44. S. S. Soldan, A. I. A. Retuerto, N. L. Sicotte, and R. R. Voskuhl, “Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol,” Journal of Immunology, vol. 171, no. 11, pp. 6267–6274, 2003. View at Google Scholar · View at Scopus
  45. T. G. Wegmann, H. Lin, L. Guilbert, and T. R. Mosmann, “Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?” Immunology Today, vol. 14, no. 7, pp. 353–356, 1993. View at Google Scholar · View at Scopus
  46. K. Hellwig, S. Schimrigk, C. Beste, T. Müller, and R. Gold, “Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis,” European Neurology, vol. 61, no. 2, pp. 65–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Michel, Y. Foucher, S. Vukusic et al., “Increased risk of multiple sclerosis relapse after in vitro fertilisation,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 83, pp. 796–802, 2012. View at Publisher · View at Google Scholar